As previously reported, Wedbush upgraded Aquestive Therapeutics to Outperform from Neutral with a price target of $4, up from $3, as a result of the $20M non-dilutive capital the company received in Q1 that the firm estimates has extended the company’s cash runway into Q2 of 2024. With this additional cash, proper expense management and the potential to raise additional non-dilutive capital through out-licensing Libervant and AQST-109, the firm is more confident in the company’s ability to finance AQST-109 through a pivotal trial, the analyst tells investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AQST:
- Aquestive Therapeutics sees FY23 revenue $37M-$41M, consensus $37.83M
- Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
- Aquestive Therapeutics reports Q4 EPS (23c), consensus (23c)
- Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
- Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
